Enhabit, Inc. (EHAB) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A indicate strong financial performance, with improved EBITDA margins, cost savings, and successful payer contract renegotiations. Despite concerns about potential rate cuts, management has strategies in place to mitigate negative impacts. The reaffirmed revenue guidance and positive cash flow conversion further support a positive outlook. The Q&A section reveals confidence in overcoming challenges, which aligns with the positive sentiment from the earnings call. Overall, the financial health and strategic initiatives suggest a positive stock price movement over the next two weeks.
Key Financial Performance
Consolidated Net Revenue $266.1 million, an increase sequentially of $6.2 million or 2.4%, with growth to the prior year of $5.5 million or 2.1%. Reasons for change include growth in both home health and hospice segments.
Consolidated Adjusted EBITDA $26.9 million, an increase sequentially of $0.3 million or 0.7%, and growing to the prior year by $1.7 million or 6.7%. Adjusted EBITDA margin as a percentage of revenue expanded to 10.1%, an increase of 40 basis points to the prior year. Reasons for change include improved profitability driven by revenue growth.
Home Health Revenue $205.9 million, reflecting sequential growth of $5.3 million or 2.6%, while lower than prior year by $4.3 million or 2.0%. Reasons for change include volume growth and stabilization of Medicare ADC, offset by unfavorable mix shift.
Home Health Adjusted EBITDA $39.3 million, reflecting a sequential increase of $1.0 million or 2.6%. Reasons for change include $3.1 million related to volume, offset by $1.5 million in yield and $0.6 million of increased expense in sales and ops back office G&A costs.
Hospice Revenue $60.2 million, reflecting sequential growth of $0.9 million or 1.5% and strong growth to prior year of $9.8 million or 19.4%. Reasons for change include double-digit volume growth and operational leverage.
Hospice Adjusted EBITDA $14.0 million, reflecting an increase to the prior year of $4.9 million or 53.8%. Adjusted EBITDA margin as a percentage of revenue improved 520 basis points to prior year, totaling 23.3%. Reasons for change include double-digit volume growth and margin expansion.
General and Administrative Expenses $26.4 million or 9.9% of revenues in Q2 compared to 10.8% in the prior year, delivering an improvement of $1.7 million or 6% year-over-year. Reasons for change include targeted cost savings initiatives, offset by merit and other inflationary increases.
Adjusted Free Cash Flow $27.8 million year-to-date, a 51.9% free cash flow conversion rate. Reasons for change include improved profitability and balance sheet improvements.
Net Debt to Adjusted EBITDA Leverage Ratio 4.3x compared to Q2 of the prior year of 5.1x. Reasons for change include debt prepayments and improved profitability.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Medalogix Implementation: Advanced process to review and approve clinician overrides by a trained virtual team of clinicians.
Hospice Expansion: Opened 1 home health and 2 hospice locations in Q2, with plans to open 10 locations in 2025 in high-growth potential areas.
Branch Closures: 11 branches closed or consolidated by Q2 2025, with plans for further consolidations in Q3.
Cost Management: Advanced visit per episode management pilot initiated in 11 branches to mitigate 2026 proposed rate cuts.
CMS Advocacy: Collaborating with the National Alliance for Care at Home to oppose CMS proposed rate cuts.
Leadership Transition: CEO Barbara Ann Jacobsmeyer announced plans to step down in July 2026, with a focus on a smooth transition to a new leader.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
CMS Proposed Rate Cuts: The CMS proposed 2026 Medicare home health rule includes continued permanent behavioral adjustments and a first-time proposed temporary adjustment, leading to cumulative rate cuts exceeding 20%. These cuts risk compromising access to home health care services, especially in rural and underserved areas, and pressure provider sustainability.
Rising Costs of Care: The rate adjustments by CMS do not reflect the increasing costs of care, exacerbated by inflation. This has forced the industry to make tough decisions, including closing locations, reducing patient access, and limiting future investments in technology and operational improvements.
Branch Closures and Consolidations: Enhabit has closed or consolidated 11 branches by the end of Q2 2025 and plans further closures. These actions are necessary to manage costs but could reduce patient access and impact service delivery.
Competitive Labor Market: The company faces challenges in recruiting and retaining skilled workforce due to a highly competitive labor market, which could impact service quality and operational efficiency.
Payer Contract Disruptions: Renegotiations with a national payer caused disruptions in admissions and census at the end of Q2, although a low double-digit increase in per visit rate was achieved.
Regulatory and Advocacy Uncertainty: Despite efforts to advocate against CMS cuts, there are no guarantees that the final rule will be less severe, creating uncertainty for future planning and operations.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company has updated its full-year revenue guidance to a range of $1.060 billion to $1.073 billion.
Adjusted EBITDA Guidance: Full-year adjusted EBITDA is now expected to be in the range of $104 million to $108 million.
Adjusted Free Cash Flow Guidance: The company expects full-year adjusted free cash flow to be in the range of $47 million to $57 million.
2026 Medicare Home Health Rule Impact: The company anticipates significant headwinds from the CMS proposed 2026 Medicare home health rule, which includes permanent and temporary rate cuts. Enhabit plans to mitigate these impacts through advanced visit per episode management, technology investments, and operational optimizations.
Growth Strategy: The company plans to open 10 new locations in 2025, focusing on areas with strong growth potential. Hospice growth is expected to continue, supported by strong operational performance and market share gains.
Operational Adjustments: Enhabit is piloting advanced visit per episode management in 11 branches to optimize care delivery and offset reimbursement challenges. Additional branch closures or consolidations may occur to manage costs.
Market Positioning: The company aims to leverage its scale, technology, and payer innovation strategy to stabilize Medicare fee-for-service volumes and gain market share in core and adjacent markets.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk about mitigating the negative impact of the proposed home nursing rule and whether operational levers can fully offset the negative 6.4%?
A:Management sees various levers in play, particularly the advanced BPE initiative. They are piloting several concepts and will assess their ability to operationalize the estimated value without impacting quality. If successful, these levers could meaningfully offset the impact once fully ramped.
Q:Can you provide details on the recent payer disruption and the impact of the new national payer contract on volumes and rates?
A:The renegotiation of a national payer resulted in a low double-digit increase in the per-visit rate. The disruption caused a census drop of about 600 or 59% of its Q2 peak between mid-June and mid-July. However, after reaching an agreement on July 11, census recovered to 76% of the peak, and admissions are now above the weekly average at 113%. Management is confident in regaining and growing census with this payer.
Q:On the proposed rate update, if the 6.4% cut is implemented, will there be follow-on cuts in subsequent years to achieve full recapture?
A:The proposed rule would be updated annually, with a framework outlined for implementation over a 7-year period. Management is focused on mitigating the immediate impact and views future adjustments as market adjustments on a prospective basis.
Q:What is causing the pressure on fee-for-service home health metrics, and how is management addressing it?
A:The pressure is due to high MA penetration in some markets and the need to redevelop referral sources in others. Management is not prioritizing other payers but aims to maintain a healthy payer mix. They are outperforming their strategy to cut the rate of decline in half and are ahead of schedule in addressing year-over-year declines.
Q:Did hospice ADC grow each month through Q2?
A:Yes, there was monthly sequential progress in Q2, but management decided to focus on quarterly progress to avoid overemphasis on minor monthly fluctuations.
Q:What are the longer-term deleveraging targets, and when might management pivot to M&A or de novo investments?
A:Management has not provided specific leverage targets but plans to continue deleveraging the balance sheet as they have over the last 5 quarters. Deleveraging remains a priority before considering M&A or other investments.
Q:Can you provide more details on the renegotiated payer contract and opportunities for similar rate increases with other contracts?
A:The renegotiated contract moved into the payer innovation contract level, allowing active pursuit of referrals. Many contracts are 3-year agreements, with more negotiations expected next year. Management starts negotiations about a year in advance.
Q:How is management addressing fee-for-service Medicare volume pressure, and what is the outlook?
A:The pressure is due to MA conversion in some markets and the need to develop referral sources with a balanced payer mix. Conversion rates on initiatives remain strong, and some markets are performing well. Management expects continued progress in the back half of the year and into next year.
Q:Can you elaborate on the pilot programs and what success metrics you are looking for?
A:The pilot involves virtual clinicians at 11 branches, with minimal costs expected. Management aims to reduce visits per episode without impacting quality. A 0.5 VPE reduction could yield $5-8 million in value, depending on capacity reallocation and patient mix. Early observations will be shared in future earnings calls.
Q:Review of Unclear Management Responses
A:Management avoided providing specific leverage targets for deleveraging and did not offer detailed metrics for the pilot programs' success, citing early stages of implementation. Additionally, they used vague language when discussing the framework for the proposed rate update and its long-term impact.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ADC
CMS home
CMS rule
Medicare home
PDGM
Research Division
Solomon Chief
access quality
addition
amortization
area
branch service
care setting
census admission
clinician
cost care
cut access
decision
digit volume
double digit
episode lever
expense
following
headwind
health rate
health rule
hospice segment
industry cost
investment technology
payer
percent basis
provider
rate adjustment
rate cut
reimbursement
rule hospice
scale
EHAB Transcript
Enhabit, Inc. (EHAB) Presents at Bank of America Home Care Conference Transcript
Neutral12-9
Enhabit, Inc. (EHAB) Presents at UBS Global Healthcare Conference 2025 Transcript
Neutral11-11
Enhabit, Inc. (EHAB) Q3 2025 Earnings Call Transcript
Unknown11-7
Despite some positive financial metrics such as revenue growth and improved EBITDA margins, the earnings call reveals concerns over Medicare revenue decline, cost structure challenges, and economic uncertainty. The Q&A section highlights unclear management responses on key issues, adding to uncertainty. The strategic plan outlines growth, but potential headwinds from regulatory changes and payer renegotiations remain. Without clear guidance, the stock price is likely to remain stable, leading to a neutral sentiment.
Enhabit, Inc. (EHAB) Q2 2025 Earnings Call Transcript
Positive8-8
The earnings call summary and Q&A indicate strong financial performance, with improved EBITDA margins, cost savings, and successful payer contract renegotiations. Despite concerns about potential rate cuts, management has strategies in place to mitigate negative impacts. The reaffirmed revenue guidance and positive cash flow conversion further support a positive outlook. The Q&A section reveals confidence in overcoming challenges, which aligns with the positive sentiment from the earnings call. Overall, the financial health and strategic initiatives suggest a positive stock price movement over the next two weeks.
EHAB Slides
EHAB Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
